| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/26/2009 | US20090082331 S1p receptor modulating compounds and use thereof |
| 03/26/2009 | US20090082330 Certain substituted amides, method of making, and method of use thereof |
| 03/26/2009 | US20090082329 Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors |
| 03/26/2009 | US20090082328 Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| 03/26/2009 | US20090082327 Deuterium-enriched meropenem |
| 03/26/2009 | US20090082326 Soluble dosage forms containing cephem derivatives suitable for parenteral administration |
| 03/26/2009 | US20090082325 Cefidinir Oral Suspension |
| 03/26/2009 | US20090082324 Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates |
| 03/26/2009 | US20090082323 Deuterium-enriched fulvestrant |
| 03/26/2009 | US20090082322 Gender Differences in Experimental Aortic Aneurysm Formation |
| 03/26/2009 | US20090082321 Steroid containing drug delivery systems |
| 03/26/2009 | US20090082320 treating weakened muscle tone, osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, by administering N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -carboxamide; agonists in bone, muscle tissue and antagonists in prostate and uterine tissues |
| 03/26/2009 | US20090082319 Deuterium-enriched budesonide |
| 03/26/2009 | US20090082318 Deuterium-enriched mometasone |
| 03/26/2009 | US20090082317 Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3 |
| 03/26/2009 | US20090082316 Composition and Method Of Stabilized Sensitive Ingredient |
| 03/26/2009 | US20090082315 Compositions and Methods for Controlling Cholesterol Levels |
| 03/26/2009 | US20090082314 Targeting Prodrugs for the Treatment of Gastrointestinal Diseases |
| 03/26/2009 | US20090082313 Multikinase Inhibitors for Use in the Treatment of Cancer |
| 03/26/2009 | US20090082312 Deuterium-enriched zoledronic acid |
| 03/26/2009 | US20090082311 2-Aminobutanol Compound and Use Thereof for Medical Purposes |
| 03/26/2009 | US20090082310 Prodrugs of thyroid hormone analogs |
| 03/26/2009 | US20090082309 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 by conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV; treating Type II diabetes but not sufficient to suppress the immune system of the animal |
| 03/26/2009 | US20090082308 histone deacetylase inhibitors; antiproliferative; antineoplastic; thioredoxin (TRX)-mediated diseases such as autoimmune, allergy, inflammatory diseases; and neurodegenerative diseases; hydroxamic acid moiety; 6-Carbamoylmethyl-benzo[b]thiophene-2-carboxylic acid (4-amino-1-phenyl-1H-pyrazol-3-yl)amide |
| 03/26/2009 | US20090082307 Culturing Lac Z-Y+ E. coli cell on glycerol and glucose in presence of lactose as exogenous precursor and isopropyl beta -D-thiogalactoside as inducer under conditions inducing the internalization according to a mechanism of active transport of exogenous precursor by cell and production of lactose |
| 03/26/2009 | US20090082306 Deuterium-enriched telbivudine |
| 03/26/2009 | US20090082305 Method of improving storage stability of substance |
| 03/26/2009 | US20090082304 Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs |
| 03/26/2009 | US20090082303 Drug for preventing and treating atherosclerosis |
| 03/26/2009 | US20090082302 Modulation of eif4e-bp2 expression |
| 03/26/2009 | US20090082301 Gene therapy for renal failure |
| 03/26/2009 | US20090082300 Modulation of transthyretin expression |
| 03/26/2009 | US20090082299 Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| 03/26/2009 | US20090082298 Methods for producing microRNAs |
| 03/26/2009 | US20090082297 Compositions and Methods for Regulating Gene Expression |
| 03/26/2009 | US20090082296 Mycobacterial antigens expressed during latency |
| 03/26/2009 | US20090082295 Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
| 03/26/2009 | US20090082294 Diagnosis, prevention and treatment of cancer |
| 03/26/2009 | US20090082293 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 03/26/2009 | US20090082292 inhibiting angiogenesis; corneal graft rejection; age related macular degeneration; diabetic retinopathy; dermatological disease |
| 03/26/2009 | US20090082291 Methods of treatment of acute renal failure |
| 03/26/2009 | US20090082290 Recombinant plasmid vector; nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter; IGF-1 signal sequence, tPA signal sequence; signal peptide encoded by a nucleotide sequence; hemodynamic-based plasmid DNA gene delivery; delivery of naked plasmid; occlusion balloon catheter |
| 03/26/2009 | US20090082289 Adenoviral vectors having a protein IX deletion |
| 03/26/2009 | US20090082288 Methods and compositions for the treatment of uveitis |
| 03/26/2009 | US20090082287 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| 03/26/2009 | US20090082286 biosynthesis to produce a renewable chemical; cultures; antioxidants, fungicides |
| 03/26/2009 | US20090082285 Adiponectin expression promoter |
| 03/26/2009 | US20090082283 Dipeptides for Prevention of Muscle Breakdown and Microbial Infection |
| 03/26/2009 | US20090082282 Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| 03/26/2009 | US20090082265 Compositions and methods for treating diseases |
| 03/26/2009 | US20090082264 123 Human Secreted Proteins |
| 03/26/2009 | US20090082263 Drug and method for improving brain function |
| 03/26/2009 | US20090082260 Combination of an immunosuppressant and a ppar gamma agonist for the treatment of an undesirable immune response |
| 03/26/2009 | US20090082256 Concomitant pharmaceutical agents and use thereof |
| 03/26/2009 | US20090082249 Nutritional supplement for a category of hiv patients |
| 03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
| 03/26/2009 | US20090081319 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| 03/26/2009 | US20090081318 Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3 |
| 03/26/2009 | US20090081314 Glycemic Control, Diabetes Treatment, and Other Treatments with Acetyl Cholinesterase Inhibitors |
| 03/26/2009 | US20090081311 Medium chain peroxycarboxylic acid compositions |
| 03/26/2009 | US20090081309 Stabilized Oral Suspension Formulation |
| 03/26/2009 | US20090081306 Microencapsulated materials and method of making same |
| 03/26/2009 | US20090081303 Pharmaceutical formulation for contraception and hormone-replacement therapy |
| 03/26/2009 | US20090081302 Pulmonary delivery of polyene antifungal agents |
| 03/26/2009 | US20090081299 Sustained release of apo a-i mimetic peptides and methods of treatment |
| 03/26/2009 | US20090081294 Sustained release dosage form for lubricating an oral cavity |
| 03/26/2009 | US20090081293 Sustained release of apo a-i mimetic peptides and methods of treatment |
| 03/26/2009 | US20090081291 Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User |
| 03/26/2009 | US20090081290 Tamper resistant dosage forms |
| 03/26/2009 | US20090081288 Orodispersible Domperidone Tablets |
| 03/26/2009 | US20090081287 Pharmaceutical Composition Containing Gelling Agent |
| 03/26/2009 | US20090081286 Extended release venlafaxine formulation |
| 03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
| 03/26/2009 | US20090081282 Pharmaceutical composition for treating cancer |
| 03/26/2009 | US20090081281 Photosensitizer Formulation for Topical Applications |
| 03/26/2009 | US20090081278 Drug Delivery System |
| 03/26/2009 | US20090081276 Bioresorbable implant composition |
| 03/26/2009 | US20090081274 Mast cell-derived renin |
| 03/26/2009 | US20090081270 Biodegradable polyurethane and polyurethane ureas |
| 03/26/2009 | US20090081263 Double-stranded rna oligonucleotides which inhibit tyrosinase expression |
| 03/26/2009 | US20090081262 Metal oxide coating of water insoluble ingredients |
| 03/26/2009 | US20090081259 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081209 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins |
| 03/26/2009 | US20090081206 Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
| 03/26/2009 | US20090081203 Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| 03/26/2009 | US20090081201 Methods for Identifying Compounds For the Treatment of Type 1 Diabetes |
| 03/26/2009 | US20090081199 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 03/26/2009 | US20090081198 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| 03/26/2009 | US20090081194 Compositions and methods for reducing risk of development, or severity, of inappropriate immune response in eyes |
| 03/26/2009 | US20090081193 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 03/26/2009 | US20090081189 Process for in vitro differentiation of neuronal stem cells or of cells derived from neuronal stem cells |
| 03/26/2009 | US20090081179 Method for reducing the severity of neurological disorders |
| 03/26/2009 | US20090081177 Methods and compositions for improving pregnancy outcome |
| 03/26/2009 | US20090081174 Synergistic fungicidal compositions |
| 03/26/2009 | US20090081172 Nucleic acid encoding a receptor other than an immunoglobulin, wherein the receptor binds to a MUC 1 tumor antigen independently of a major histocompatibility complex (MHC); activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor |
| 03/26/2009 | US20090081165 Bicyclic heteroaryl derivatives |
| 03/26/2009 | US20090081163 Cladribine regimen for treating multiple sclerosis |
| 03/26/2009 | US20090081161 Treatment of neoplasms with viruses |
| 03/26/2009 | US20090081158 Phosphadiazine hcv polymerase inhibitors iv |